Company intelligence / Profile preview

Blaze Bioscience

Seattle, Washington, United Statesblazebioscience.com ↗

Ownership: Private
Employees: ~17
Development stage: Phase 2

Overview

Completed enrollment for pivotal Phase 2/3 trial of tozuleristide and the Canvas Imaging System in pediatric central nervous system tumors. BLZ-100 (tozuleristide) received Fast Track Designation from FDA for pediatric central nervous system tumors. Clinical proof-of-concept has been demonstrated in brain, breast, and skin cancer.

Therapeutic areas: Oncology
Modalities: Fluorescence-guided cancer surgery productspeptide-based imaging agents
Industry: Biotech

Drug pipeline

2 assets

tozuleristide

1 more asset in the full pipeline.

Request access →

Partnerships

Fred Hutchinson Cancer Research CenterPacific Pediatric Neuro-Oncology Consortium (PNOC)unidentified pharmaceutical company for immuno-oncology pipeline

Beyond the preview

Go deeper on Blaze Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blaze Bioscience.

Explore the full profile